Literature DB >> 28819720

Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.

Tao Wang1, Zsofia K Stadler2, Liying Zhang1, Martin R Weiser3, Olca Basturk1, Jaclyn F Hechtman1, Efsevia Vakiani1, Lenard B Saltz2, David S Klimstra1, Jinru Shia4.   

Abstract

Microsatellite instability, a well-established driver pathway in colorectal carcinogenesis, can develop in both sporadic and hereditary conditions via different molecular alterations in the DNA mismatch repair (MMR) genes. MMR protein immunohistochemistry (IHC) is currently widely used for the detection of MMR deficiency in solid tumors. The IHC test, however, can show varied staining patterns, posing challenges in the interpretation of the staining results in some cases. Here we report a case of an 80-year-old female with a colonic adenocarcinoma that exhibited an unusual "null" IHC staining pattern with complete loss of all four MMR proteins (MLH1, MSH2, MSH6, and PMS2). This led to subsequent MLH1 methylation testing and next generation sequencing which demonstrated that the loss of all MMR proteins was associated with concurrent promoter hypermethylation of MLH1 and double somatic truncating mutations in MSH2. These molecular findings, in conjunction with the patient's age being 80 years and the fact that the patient had no personal or family cancer history, indicated that the MMR deficiency was highly likely sporadic in nature. Thus, the stringent Lynch syndrome type surveillance programs were not recommended to the patient and her family members. This case illustrates a rare but important scenario where a null IHC phenotype signifies complex underlying molecular alternations that bear clinical management implications, highlighting the need for recognition and awareness of such unusual IHC staining patterns.

Entities:  

Keywords:  Double somatic mutation; Lynch syndrome; MLH1 methylation; MMR immunohistochemistry; Microsatellite instability; Next generation sequencing

Mesh:

Substances:

Year:  2018        PMID: 28819720      PMCID: PMC5908711          DOI: 10.1007/s10689-017-0031-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  15 in total

1.  "Null pattern" of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation.

Authors:  Catherine E Hagen; Joel Lefferts; Jason L Hornick; Amitabh Srivastava
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

2.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

Review 3.  Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma.

Authors:  Jinru Shia
Journal:  Semin Diagn Pathol       Date:  2015-02-04       Impact factor: 3.464

4.  Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients.

Authors:  Dagmara Dymerska; Pablo Serrano-Fernández; Janina Suchy; Andrzej Pławski; Ryszard Słomski; Krzysztof Kaklewski; Rodney J Scott; Jacek Gronwald; Józef Kładny; Tomasz Byrski; Tomasz Huzarski; Jan Lubiński; Grzegorz Kurzawski
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

5.  The Pfam protein families database.

Authors:  Robert D Finn; Jaina Mistry; John Tate; Penny Coggill; Andreas Heger; Joanne E Pollington; O Luke Gavin; Prasad Gunasekaran; Goran Ceric; Kristoffer Forslund; Liisa Holm; Erik L L Sonnhammer; Sean R Eddy; Alex Bateman
Journal:  Nucleic Acids Res       Date:  2009-11-17       Impact factor: 16.971

6.  Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency.

Authors:  Jinru Shia; Liying Zhang; Moshe Shike; Min Guo; Zsofia Stadler; Xiaoling Xiong; Laura H Tang; Efsevia Vakiani; Nora Katabi; Hangjun Wang; Ruben Bacares; Jeanine Ruggeri; C Richard Boland; Marc Ladanyi; David S Klimstra
Journal:  Mod Pathol       Date:  2012-08-24       Impact factor: 7.842

7.  Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors.

Authors:  Isabelle Sourrouille; Florence Coulet; Jeremie H Lefevre; Chrystelle Colas; Mélanie Eyries; Magali Svrcek; Armelle Bardier-Dupas; Yann Parc; Florent Soubrier
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

8.  Biallelic MUTYH mutations can mimic Lynch syndrome.

Authors:  Monika Morak; Barbara Heidenreich; Gisela Keller; Heather Hampel; Andreas Laner; Albert de la Chapelle; Elke Holinski-Feder
Journal:  Eur J Hum Genet       Date:  2014-02-12       Impact factor: 4.246

9.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.

Authors:  Jinru Shia
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

10.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.

Authors:  Beifang Niu; Kai Ye; Qunyuan Zhang; Charles Lu; Mingchao Xie; Michael D McLellan; Michael C Wendl; Li Ding
Journal:  Bioinformatics       Date:  2013-12-25       Impact factor: 6.937

View more
  7 in total

1.  Correlation of MLH1 polymorphisms, survival statistics, in silico assessment and gene downregulation with clinical outcomes among breast cancer cases.

Authors:  Saima Shakil Malik; Ayisha Zia; Sumaira Mubarik; Nosheen Masood; Sajid Rashid; Alice Sherrard; Muhammad Bilal Khan; Muhammad Tahir Khadim
Journal:  Mol Biol Rep       Date:  2019-11-08       Impact factor: 2.316

2.  An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes.

Authors:  Marion Jaffrelot; Nadim Farés; Rosine Guimbaud; Janick Selves; Anne Cécile Brunac; Anne Pascale Laurenty; Marie Danjoux; David Grand; Samira Icher; Julie Meilleroux; Eliane Mery; Etienne Buscail; Charlotte Maulat; Christine Toulas; Pierre Vande Perre; Edith Chipoulet; Delphine Bonnet; Anne Staub
Journal:  Mod Pathol       Date:  2021-09-20       Impact factor: 7.842

3.  Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.

Authors:  Neil H Segal; Andrea Cercek; Geoffrey Ku; Abraham J Wu; Andreas Rimner; Danny N Khalil; Diane Reidy-Lagunes; John Cuaron; T Jonathan Yang; Martin R Weiser; Paul B Romesser; Zsofia K Stadler; Anna M Varghese; Karuna Ganesh; Rona Yaeger; Louise C Connell; David Faleck; Ghassan K Abou-Alfa; Kathleen C Mcauliffe; Pamela Vaiskauskas; Mark L Solter; Martinique Ogle; Matthew J Adamow; Aliya Holland; Pallavi Vedantam; Phillip Wong; Taha Merghoub; Efsevia Vakiani; Travis J Hollmann; Krishna Juluru; Joanne F Chou; Marinela Capanu; Joseph Erinjeri; Stephen Solomon; Yoshiya Yamada; Nancy Kemeny; Christopher H Crane; Leonard B Saltz
Journal:  Clin Cancer Res       Date:  2021-01-27       Impact factor: 12.531

4.  Controlling for cellular heterogeneity using single-cell deconvolution of gene expression reveals novel markers of colorectal tumors exhibiting microsatellite instability.

Authors:  Matthew A M Devall; Graham Casey
Journal:  Oncotarget       Date:  2021-04-13

5.  High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers.

Authors:  Ling Zhang; Zheng-Shuai Song; Zhi-Shun Wang; Yong-Lian Guo; Chang-Geng Xu; Hao Shen
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244

6.  Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation.

Authors:  Melanie Demes; Ursula Pession; Jan Jeroch; Falko Schulze; Katrin Eichler; Daniel Martin; Peter Wild; Oliver Waidmann
Journal:  Oncotarget       Date:  2022-09-14

7.  Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma.

Authors:  Alicia Latham; Jinru Shia; Zalak Patel; Diane L Reidy-Lagunes; Neil H Segal; Rona Yaeger; Karuna Ganesh; Louise Connell; Nancy E Kemeny; David P Kelsen; Jaclyn F Hechtman; Garrett M Nash; Philip B Paty; Ahmet Zehir; Kaitlin A Tkachuk; Rania Sheikh; Arnold J Markowitz; Diana Mandelker; Kenneth Offit; Michael F Berger; Andrea Cercek; Julio Garcia-Aguilar; Leonard B Saltz; Martin R Weiser; Zsofia K Stadler
Journal:  Clin Cancer Res       Date:  2020-11-16       Impact factor: 13.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.